Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

BACKGROUND: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer. New Adjuvant Trial with Ribociclib [LEE011] (NATALEE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Slamon, Dennis J., Fasching, Peter A., Hurvitz, Sara, Chia, Stephen, Crown, John, Martín, Miguel, Barrios, Carlos H., Bardia, Aditya, Im, Seock-Ah, Yardley, Denise A., Untch, Michael, Huang, Chiun-Sheng, Stroyakovskiy, Daniil, Xu, Binghe, Moroose, Rebecca L., Loi, Sherene, Visco, Frances, Bee-Munteanu, Valerie, Afenjar, Karen, Fresco, Rodrigo, Taran, Tetiana, Chakravartty, Arunava, Zarate, Juan Pablo, Lteif, Agnes, Hortobagyi, Gabriel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233570/
https://www.ncbi.nlm.nih.gov/pubmed/37275963
http://dx.doi.org/10.1177/17588359231178125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233570/
https://www.ncbi.nlm.nih.gov/pubmed/37275963
http://dx.doi.org/10.1177/17588359231178125

Ejemplares similares